BCRX
NASDAQ · Biotechnology
Biocryst Pharmaceuticals Inc
$9.38
+0.08 (+0.86%)
Open$9.50
Previous Close$9.30
Day High$9.67
Day Low$9.23
52W High$11.22
52W Low$6.00
Volume—
Avg Volume3.27M
Market Cap2.40B
P/E Ratio—
EPS$-1.78
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+604.9% upside
Current
$9.38
$9.38
Target
$66.12
$66.12
$46.17
$66.12 avg
$78.89
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.07B | 724.18M | 328.14M |
| Net Income | 322.91M | 196.59M | -56,674,354 |
| Profit Margin | 30.2% | 28.7% | -17.3% |
| EBITDA | 397.78M | 255.62M | -75,730,538 |
| Free Cash Flow | — | — | -52,199,092 |
| Rev Growth | +47.8% | +47.8% | +7.1% |
| Debt/Equity | 2.09 | 2.09 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |